170030-57-6

Basic information

• Product Name: 6-amino-3-methyl-1-phenyl-4-(3,4,5-trimethoxyphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
• Synonyms: 6-amino-3-methyl-1-phenyl-4-(3,4,5-trimethoxyphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile
• CAS NO: 170030-57-6
• Molecular Formula: C₂₃H₂₂N₄O₄
• Molecular Weight: 418.44518
• Mol File: 170030-57-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-amino-3-methyl-1-phenyl-4-(3,4,5-trimethoxyphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-amino-3-methyl-1-phenyl-4-(3,4,5-trimethoxyphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile(170030-57-6)
• EPA Substance Registry System: 6-amino-3-methyl-1-phenyl-4-(3,4,5-trimethoxyphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile(170030-57-6)

Safety Data

• Hazardous Substances Data: 170030-57-6(Hazardous Substances Data)

Upstream product

• 5688-82-4 2-(3,4,5-trimethoxybenzylidene)malononitrile 
• 89-25-8 edaravone 
• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 109-77-3 malononitrile 
• 19735-89-8 3-methyl-1-phenylpyrazolin-5(4H)-one 
• 100-63-0 phenylhydrazine 

Downstream Products

• 170030-58-7 6-ethoxymethylideneamino-3-methyl-1-phenyl-4-(3,4,5-trimethoxyphenyl)-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile 
• 170030-59-8 5-imino-3-methyl-1-phenyl-4-(3,4,5-trimethoxyphenyl)-1,4,5,6-tetrahydropyrazolo[4',3':5,6]pyrano[2,3-d]pyrimidin-6-amine 

Relevant articles and documents

Behaviour of some activated nitriles toward barbituric, thiobarbituric acids and 3-methyl-1-phenylpyrazol-5-one

The effect of some active methylene containing heterocyclic compounds, namely barbituric, thiobarbituric acids and 3-mehtyl-1-phenylpyrazol-5-one on α-cyano-3,4,5-trimethoxycinnamonitrile and ethyl α-cyano-3,4,5-trimethoxycinnamate 1a, b was investigated.

Amberlite-supported L-prolinate: A novel heterogeneous organocatalyst for the three-component synthesis of 4H-pyrano[2,3-c]pyrazole derivatives

This report describes a new and convenient procedure for heterogenization of L-proline organocatalyst, which is based on non-covalent immobilization of L-proline on the surface of anion-exchange resin amberlite IRA900OH (AmbIRA900OH) as an efficient, chea

Ligand based design and synthesis of pyrazole based derivatives as selective COX-2 inhibitors

The design and synthesis of novel pyrazole based derivatives has been carried out using the ligand based approach like pharmacophore and QSAR modelling of reported pyrazoles from the available literature to investigate the chemical features that are essential for the design of selective and potent COX-2 inhibitors. Both pharmacophore and QSAR models with good statistical parameters were selected for the design of the lead molecule. Also by exploiting the chemical structures of selective and marketed COX-2 inhibitors, celecoxib and SC-558 were used in designing the molecules which are used in the treatment of inflammation and related disorders. The therapeutic action of the Non-Steroidal Anti-inflammatory Agents (NSAIDs) is based primarily on the COX-2 inhibition. With this background we have synthesized some azomethine derivatives of 3-methyl-1-substituted-4-phenyl-6-[{(1E)-phenylmethylene}amino]-1,4-dihydro pyrano[2,3-c]pyrazole-5-carbonitrile 6(a-o) and were characterized by 1HNMR, 13CNMR and Mass spectral techniques. All the synthesized pyrazole derivatives were tested for in vitro membrane stability property in both COX-1 & COX-2 inhibition studies and in vivo anti-inflammatory activity by carrageenan induced rat paw edema model. Among them, compound 6k showed very good activity by in vivo anti-inflammatory activity with 0.8575 mmol/kg as ED50. Similarly compounds 6m, 6o, 6i and 6h exhibited comparable anti-inflammatory activity to standard drugs. Also the active compounds were further screened for ulcerogenic activity and were found be safer with less ulcer index compared to the marketed drugs like aspirin, ibuprofen and celecoxib.